Health & Fit ImmunoGen ends losing streak as William Blair cites cancer guidance
Now You Can Screen for Cancer Sooner Rather Than Later
The latest tests may give you a leg up on a deadly disease. When these annual screenings are as simple as a blood test, they could indeed become common practice. Multi-cancer early detection (MCED) tests can reveal cancers—including those with no recommended screenings—with a single blood draw. Here’s why these tests could be valuable enough to become part of your annual physical. Many cancers can be detected months or years earlier than they currently areThe U.S.
Oncology-focused biotech ImmunoGen (NASDAQ:) ended a four-day skid on Wednesday after William Blair pointed to guidelines from the National Comprehensive Cancer (NCCN) to support the potential of the company’s recently approved ovarian cancer therapy Elahere.
Amid concerns over the $6K price tag for Elahere ImmunoGen () shares fell in November, a day after its FDA approval for certain adults with FRα-high
However, William Blair analyst Andy Hsieh thinks the NCCN guidelines for ovarian cancer treatment will improve its uptake.
“We are encouraged to see Elahere listed as both a preferred monotherapy and a combination regimen with Avastin in some scenarios,” the analyst wrote.
Can You Get Lung Cancer If You've Never Smoked?
Most are aware of the risks of developing lung cancer, especially those who smoke. But what about those who have never touched a cigarette in their life?Statistics from the Centers for Disease Control and Prevention (CDC) show that about 10% to 20% of lung cancer-related cases occur in people who've never picked up a single cigarette or those who've smoked less than 100 cigarettes in their entire life. This proves lung cancer can be just as dangerous in smokers as in non-smokers. Lung cancer in non-smokers is even considered one of the most deadly cancers in the United States, reveals the American Cancer Society.
“The latter was a particular surprise to the upside, since it occurred faster than our (and likely the Street’s) expectations,” Hsieh added, referring to a combination therapy involving Elahere and Roche’s () ( ) cancer therapy Avastin.
“It is our view that the NCCN listing as a preferred regimen will boost physician uptake of Elahere, given that NCCN continues to be one of the most reliable guidelines among oncologists,” Hsieh said.
Targeting an FDA label expansion, the company has designed a Phase 3 study to evaluate Elahere in combination with Avastin as maintenance therapy in FRα-
Read: Seeking Alpha contributor Jonathan Faison thinks that ImmunoGen () “has a first-mover opportunity with Elahere in an indication (platinum-resistant
10 Signs Of Ovarian Cancer You May Be Overlooking .
For those with ovarian cancer, early detection of the disease is vital. However, many symptoms might be overlooked. Here's what you should look out for.According to the American Cancer Society, approximately 19,880 women will be diagnosed with ovarian cancer in the United States this year. Furthermore, the disease will claim the lives of more than 12,000 women. Ovarian cancer is the leading cause of death among female reproductive cancers.